Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE: OLN324 in nAMD and DME
NCT07484074Phase 1Completed
- Sponsor
- Ollin Biosciences
- Start
- Feb 2025
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised trial of OLN324 in diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Ollin Biosciences. Primary endpoint: Adverse Events at 20 weeks. Started Feb 2025; status: completed.
02
Drugs
OLN324
03
Conditions
diabetic macular edema (DME)neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07484074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07484074.